CHROMIC SULFATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2Cr.3O4S
Molecular Weight	392.18
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O

InChI

InChIKey=GRWVQDDAKZFPFI-UHFFFAOYSA-H

InChI=1S/2Cr.3H2O4S/c;;3*1-5(2,3)4/h;;3*(H2,1,2,3,4)/q2*+3;;;/p-6

HIDE SMILES / InChI

Molecular Formula	Cr
Molecular Weight	51.9961
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	O4S
Molecular Weight	96.063
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10630581 | https://www.ncbi.nlm.nih.gov/pubmed/28954488

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
transmembrane receptor protein tyrosine kinase activity 22 Target ID: GO:0004714 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15924436	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chromium deficiency 22 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4d01ebb-a36e-44b7-028c-43c0ab2d13b4	Preventing		Approved 8429	CHROMIUM Approved Use Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. Launch Date 1.12000316E12

PubMed

Title	Date	PubMed
Activation of MAPKs in human bronchial epithelial cells exposed to metals.	1998 Sep	9728050
Thirteen-week subchronic rat inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic oxide, and basic chromium sulfate.	1999 Dec	10630581
The role of oxidative stress in the modulation of aryl hydrocarbon receptor-regulated genes by As3+, Cd2+, and Cr6+.	2005 Dec 1	16274885
The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment.	2017 Sep 21	28954488

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:19:28 UTC 2023` Edited by `admin` on `Fri Dec 15 16:19:28 UTC 2023`
Record UNII	Y0C99N5TMZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHROMIC SULFATE

Common Name

English

CHROMIUM SULFATE (2:3)

Systematic Name

English

CHROMIUM(III) SULFATE [HSDB]

Common Name

English

CHROMIUM(III) SULPHATE

Systematic Name

English

CHROMIC SULPHATE

Common Name

English

CHROMIC SULFATE [MI]

Common Name

English

DICHROMIUM TRISULPHATE

Systematic Name

English

CHROMIUM III SULPHATE

Common Name

English

CHROMIUM SULPHATE (2:3)

Systematic Name

English

NSC-51151

Code

English

DICHROMIUM TRISULFATE

Systematic Name

English

CHROMIC SULFATE [VANDF]

Common Name

English

CHROMIUM(III) SULFATE

Systematic Name

English

CHROMIUM III SULFATE

Common Name

English

Code System Code Type Description

CAS

10101-53-8